Nilotinib price per box and cost update in 2025

Nilotinib is a targeted drug used to treat chronic myelogenous leukemia (CML). It is a second-generation BCR-ABL tyrosine kinase inhibitor with stronger target selectivity and lower drug resistance rate. In the Chinese mainland market, nilotinib is marketed under the trade name "Tasigna" (Tasigna) and is included in the Category B scope of the National Reimbursement Directory. It is mainly used to treat PhPhpositiveCML chronic phase patients who are resistant or intolerant to imatinib treatment. The prerequisite for medical insurance reimbursement is that it meets specific indication conditions and must pass the medical insurance review process in accordance with regulations.

In terms of price, the current common specification of the original version of nilotinib marketed in China is 150mg*120 tablets, with each box selling for about 1 RMB. Although the price is higher, reimbursement through medical insurance can alleviate some of the financial burden. Since this drug is a long-term medication, the financial pressure on patients cannot be ignored, especially when they do not meet the conditions for medical insurance reimbursement or need to purchase the drug at their own expense. Finding more economical alternatives has become the focus of many patients.

In overseas markets, nilotinib has also been on the market for a long time, and the price of the original version in India is more affordable than in China. It is understood that the Indian version of the original drug 150mg*120 capsules is priced at about 2,000 yuan per box, with obvious price advantages. These drugs are mostly purchased through formal cross-border medical platforms, and their efficacy is basically the same as the domestic version. However, due to exchange rate changes and international logistics, the price may fluctuate to a certain extent. It is recommended that patients purchase drugs through qualified channels to ensure drug quality and safety.

In addition, some generic versions of nilotinib produced by pharmaceutical companies in Laos and other countries have also appeared on the market, such as 150mg*28 tablets. The price per box is only 1,000 multiple yuan. The ingredients of this type of generic drugs are highly consistent with the original drugs, and they have obtained legal marketing authorization in some countries. They are an important alternative for many patients with heavy financial burdens. Overall, the medication cost of nilotinib in 2025 presents a multi-level choice between the original drug, the Indian version and generic drugs. Patients can make reasonable purchases based on their condition, financial status and doctor's advice.

Reference materials:https://www.drugs.com/